发布求助
文献互助 智能选刊 最新文献

Australian Prescriber最新文献

筛选
英文 中文
Male and female pattern hair loss. 男性和女性的脱发模式。
IF 3.4
Australian Prescriber Pub Date : 2025-06-01 DOI: 10.18773/austprescr.2025.020
Laxmi Iyengar, Jane Li
{"title":"Male and female pattern hair loss.","authors":"Laxmi Iyengar, Jane Li","doi":"10.18773/austprescr.2025.020","DOIUrl":"10.18773/austprescr.2025.020","url":null,"abstract":"<p><p>Androgenetic alopecia, commonly referred to as male or female pattern hair loss, is a prevalent condition encountered in clinical practice. It is important to identify potential underlying causes and differentiate it from other forms of hair loss, which may require referral to a dermatologist for management. Pharmacological treatments for female pattern hair loss include minoxidil (topical and oral) and antiandrogens such as spironolactone. For male pattern hair loss, minoxidil and 5-alpha-reductase inhibitors (e.g. finasteride, dutasteride) can be used. Combination therapy is commonly employed, with clinical improvement typically requiring a minimum of 6 months. Supplements and other treatments have varying levels of evidence, and counselling is important to help patients make informed decisions about their management.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 3","pages":"93-97"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Talazoparib for prostate cancer and breast cancer. Talazoparib治疗前列腺癌和乳腺癌。
IF 3.4
Australian Prescriber Pub Date : 2025-06-01 DOI: 10.18773/austprescr.2025.027
{"title":"Talazoparib for prostate cancer and breast cancer.","authors":"","doi":"10.18773/austprescr.2025.027","DOIUrl":"10.18773/austprescr.2025.027","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 3","pages":"111-113"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using pharmacogenomics to personalise drug therapy: which drugs, when and how. 使用药物基因组学来个性化药物治疗：哪些药物，何时以及如何使用。
IF 3.4
Australian Prescriber Pub Date : 2025-06-01 DOI: 10.18773/austprescr.2025.021
Sophie L Stocker, Thomas M Polasek
{"title":"Using pharmacogenomics to personalise drug therapy: which drugs, when and how.","authors":"Sophie L Stocker, Thomas M Polasek","doi":"10.18773/austprescr.2025.021","DOIUrl":"10.18773/austprescr.2025.021","url":null,"abstract":"<p><p>Pharmacogenomic testing provides information on whether a patient possesses gene variants that can influence drug exposure or response. It can be used as part of clinical decision-making to personalise drug therapy. Pharmacogenomic testing can help identify patients at higher risk of serious adverse drug reactions or therapeutic failure, and sometimes it can explain unexpected adverse effects or poor efficacy in patients already on drug therapy. As drug responses are influenced by many factors, pharmacogenomic test results must always be interpreted in the clinical context of the patient. At the time of writing, tests for thiopurine methyltransferase (TPMT) (azathioprine, mercaptopurine, thioguanine) and human leucocyte antigen B*57:01 (abacavir) are Medicare-rebated. Pharmacogenomic testing is also recommended for several other drugs, such as allopurinol and clopidogrel, but these do not currently attract a Medicare rebate.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 3","pages":"82-86"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Icosapent ethyl and gastrointestinal bleeds. 乙基戊二醇和胃肠道出血。
IF 3.4
Australian Prescriber Pub Date : 2025-04-01 DOI: 10.18773/austprescr.2025.014
Stephanie Ternel
{"title":"Icosapent ethyl and gastrointestinal bleeds.","authors":"Stephanie Ternel","doi":"10.18773/austprescr.2025.014","DOIUrl":"https://doi.org/10.18773/austprescr.2025.014","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 2","pages":"62"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Diagnosis and management of antiphospholipid syndrome [Erratum]. 勘误：抗磷脂综合征的诊断和治疗[勘误]。
IF 3.4
Australian Prescriber Pub Date : 2025-04-01 DOI: 10.18773/austprescr.2025.011
{"title":"Erratum: Diagnosis and management of antiphospholipid syndrome [Erratum].","authors":"","doi":"10.18773/austprescr.2025.011","DOIUrl":"https://doi.org/10.18773/austprescr.2025.011","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.18773/austprescr.2024.055.].</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 2","pages":"69"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nelarabine for T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma. 奈拉滨治疗t细胞急性淋巴细胞白血病和t细胞淋巴细胞淋巴瘤。
IF 3.4
Australian Prescriber Pub Date : 2025-04-01 DOI: 10.18773/austprescr.2025.016
{"title":"Nelarabine for T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma.","authors":"","doi":"10.18773/austprescr.2025.016","DOIUrl":"https://doi.org/10.18773/austprescr.2025.016","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 2","pages":"65-66"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144058412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Calcitonin gene-related peptide-targeted therapies for migraine. 降钙素基因相关肽靶向治疗偏头痛。
IF 3.4
Australian Prescriber Pub Date : 2025-04-01 DOI: 10.18773/austprescr.2025.017
Stephanie Barnes, Lucie Aldous, Bronwyn Jenkins
{"title":"Calcitonin gene-related peptide-targeted therapies for migraine.","authors":"Stephanie Barnes, Lucie Aldous, Bronwyn Jenkins","doi":"10.18773/austprescr.2025.017","DOIUrl":"https://doi.org/10.18773/austprescr.2025.017","url":null,"abstract":"<p><p>Calcitonin gene-related peptide (CGRP)-targeted therapies are the first medications developed specifically for migraine prevention. They block the actions of CGRP, a neuropeptide with a key role in migraine pathophysiology. There are 2 categories of drugs: monoclonal antibodies directed against either the CGRP ligand or receptor, and small-molecule CGRP receptor antagonists. CGRP monoclonal antibodies are available as self-administered subcutaneous injections or as an intravenous infusion, and are administered monthly or quarterly. Clinical trial and real-world data over the past 10 years support their effectiveness and safety in patients with episodic and chronic migraines, and research into long-term safety is ongoing. Patients must fulfil certain criteria, including prior treatment with nonspecific oral preventive medications, to receive subsidised treatment with these drugs on the Pharmaceutical Benefits Scheme (PBS) in Australia. Small-molecule CGRP receptor antagonists (known as gepants) are orally administered drugs that can be used for migraine prevention or acute treatment. There are no gepants listed on the PBS at the time of writing. Their role in the prevention and acute treatment of migraine is continuing to evolve.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 2","pages":"40-46"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lenacapavir for multidrug-resistant HIV-1 infection. Lenacapavir治疗耐多药HIV-1感染。
IF 3.4
Australian Prescriber Pub Date : 2025-04-01 DOI: 10.18773/austprescr.2025.012
{"title":"Lenacapavir for multidrug-resistant HIV-1 infection.","authors":"","doi":"10.18773/austprescr.2025.012","DOIUrl":"https://doi.org/10.18773/austprescr.2025.012","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 2","pages":"63-64"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144044893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clonazepam oral liquid: confusion between drops, milligrams and millilitres. 氯硝西泮口服液：分不清滴剂、毫克和毫升。
IF 3.4
Australian Prescriber Pub Date : 2025-04-01 DOI: 10.18773/austprescr.2025.015
Joey Chan, Abigail E Franklin
{"title":"Clonazepam oral liquid: confusion between drops, milligrams and millilitres.","authors":"Joey Chan, Abigail E Franklin","doi":"10.18773/austprescr.2025.015","DOIUrl":"https://doi.org/10.18773/austprescr.2025.015","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 2","pages":"60-61"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safe and effective use of vancomycin. 万古霉素的安全有效使用。
IF 4.2
Australian Prescriber Pub Date : 2025-04-01 DOI: 10.18773/austprescr.2025.013
Amy Legg, Felicia Devchand, Amanda Gwee, Indy Sandaradura, Tony Lai
{"title":"Safe and effective use of vancomycin.","authors":"Amy Legg, Felicia Devchand, Amanda Gwee, Indy Sandaradura, Tony Lai","doi":"10.18773/austprescr.2025.013","DOIUrl":"10.18773/austprescr.2025.013","url":null,"abstract":"<p><p>Vancomycin is an important antimicrobial for prophylactic, empirical and directed therapy of Gram-positive organisms. Therapeutic drug monitoring is recommended for all patients expected to receive vancomycin for more than 48 hours to optimise drug exposure. Monitoring the area under the concentration-time curve over a 24-hour period (AUC<sub>24</sub>) for vancomycin is preferred over monitoring trough plasma concentrations. An AUC<sub>24</sub> of 400 to 600 mg.hr/L is recommended for infections other than central nervous system infections. Vancomycin may cause nephrotoxicity, ototoxicity, cutaneous reactions, hypersensitivity and haematological toxicity. Reducing the incidence of vancomycin-induced nephrotoxicity involves recognising and modifying risk factors where possible.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 2","pages":"54-59"},"PeriodicalIF":4.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书